Dyne Therapeutics, Inc. · NASDAQ:DYN

Rhodes Jason P sold 267,760 Dyne Therapeutics, Inc. shares (Form 4)

Traded Jun 23 to Jun 25, 2026 · Filed Jun 26, 2026

From Jun 23 to Jun 25, 2026, Rhodes Jason P (Director) sold 267,760 Dyne Therapeutics, Inc. shares at an average US$21.09 for US$5.65M under a trading plan, leaving 1,081,044 shares. Filed Jun 26, 2026 (Form 4).

Sold
267,760 shares
Price
US$21.09 average (US$21.02 to US$21.13)
Value
US$5.65M
Holding after
1,081,044 shares (held indirectly)
Trading plan
Yes (Made under a plan set in advance)
Role
Director

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 23, 2026Common StockSale77,855US$21.134,805,639Indirect
Jun 23, 2026Common StockSale39,131US$21.131,510,157Indirect
Jun 23, 2026Common StockSale30,774US$21.131,106,036Indirect
Jun 24, 2026Common StockSale50,530US$21.024,755,109Indirect
Jun 24, 2026Common StockSale25,397US$21.021,484,760Indirect
Jun 24, 2026Common StockSale19,973US$21.021,086,063Indirect
Jun 25, 2026Common StockSale12,699US$21.104,742,410Indirect
Jun 25, 2026Common StockSale6,382US$21.101,478,378Indirect
Jun 25, 2026Common StockSale5,019US$21.101,081,044Indirect

Source

View original at SEC

Related